CompletedNCT03403790
A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolarity
Observational studyJapan
Understand this study
Who was this study for?
This study was for people with bipolarity. Other eligibility criteria applied.
- Listed locations
- Aichi and 46 more locationsSee all locations and recruitment
Study information
Study start dateStarted: January 15, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 369
- Sponsor
- Astellas Pharma Inc
- Sponsor type
- Pharmaceutical company
- Study type
- Observational
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- Japan
- Age range
- Not clearly listed
- Official registry ID
- NCT03403790
- Official title
Show the full official title
Drug Use-results Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder
Get this study by email
Recruitment & locations
CompletedAichi · Akita · Aomori
44 more locations
- Chiba
- Ehime
- Fukui
- Fukuoka
- Fukushima
- Gifu
- Gunma
- Hiroshima
- Hokkaido
- Hyōgo
- Ibaraki
- Ishikawa
- Kagawa
- Kagoshima
- Kanagawa
- Kochi
- Kumamoto
- Kyoto
- Mie
- Miyagi
- Miyazaki
- Nagano
- Nagasaki
- Nara
- Niigata
- Numakunai
- Okayama
- Okinawa
- Osaka
- Ōita
- Saga
- Saitama
- Shiga
- Shimane
- Shizuoka
- Tochigi
- Tokushima
- Tokyo
- Tottori
- Toyama
- Wakayama
- Yamagata
- Yamaguchi
- Yamanashi
Questions about this study
Who is behind this study?
The study sponsor is Astellas Pharma Inc, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine.
Who was this study for?
This study was for people with bipolarity. Other eligibility criteria applied.
